Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14,521 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.
Sumida Y, Yoneda M, Seko Y, Ishiba H, Hara T, Toyoda H, Yasuda S, Kumada T, Hayashi H, Kobayashi T, Imajo K, Yoneda M, Tada T, Kawaguchi T, Eguchi Y, Oeda S, Takahashi H, Tomita E, Okanoue T, Nakajima A, Japan Study Group Of Nafld Jsg-Nafld. Sumida Y, et al. Among authors: kobayashi t. Diagnostics (Basel). 2020 Aug 10;10(8):579. doi: 10.3390/diagnostics10080579. Diagnostics (Basel). 2020. PMID: 32785100 Free PMC article. Review.
Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A randomized, open-label pilot study (ToPiND study).
Ozaki A, Yoneda M, Kessoku T, Iwaki M, Kobayashi T, Honda Y, Ogawa Y, Imajo K, Sakai E, Taguri M, Yamanaka T, Iwasaki T, Kurihashi T, Saito S, Nakajima A. Ozaki A, et al. Among authors: kobayashi t. Contemp Clin Trials Commun. 2019 Dec 31;17:100516. doi: 10.1016/j.conctc.2019.100516. eCollection 2020 Mar. Contemp Clin Trials Commun. 2019. PMID: 31956725 Free PMC article.
Efficacy and safety of PERIOdontal treatment versus usual care for Nonalcoholic liver disease: protocol of the PERION multicenter, two-arm, open-label, randomized trial.
Kamata Y, Kessoku T, Shimizu T, Kobayashi T, Kurihashi T, Sato S, Kuraji S, Aoyama N, Iwasaki T, Takashiba S, Hamada N, Kodama T, Tamura T, Ino S, Higurashi T, Taguri M, Yamanaka T, Yoneda M, Usuda H, Wada K, Nakajima A, Minabe M. Kamata Y, et al. Among authors: kobayashi t. Trials. 2020 Mar 23;21(1):291. doi: 10.1186/s13063-020-4201-y. Trials. 2020. PMID: 32293522 Free PMC article. Clinical Trial.
Diagnostic accuracy of FibroScan-AST score to identify non-alcoholic steatohepatitis with significant activity and fibrosis in Japanese patients with non-alcoholic fatty liver disease: Comparison between M and XL probes.
Oeda S, Takahashi H, Imajo K, Seko Y, Kobayashi T, Ogawa Y, Moriguchi M, Yoneda M, Anzai K, Irie H, Sueoka E, Aishima S, Kage M, Itoh Y, Eguchi Y, Nakajima A. Oeda S, et al. Among authors: kobayashi t. Hepatol Res. 2020 Jul;50(7):831-839. doi: 10.1111/hepr.13508. Epub 2020 May 13. Hepatol Res. 2020. PMID: 32337818
Metabolomic/lipidomic-based analysis of plasma to diagnose hepatocellular ballooning in patients with non-alcoholic fatty liver disease: A multicenter study.
Ogawa Y, Kobayashi T, Honda Y, Kessoku T, Tomeno W, Imajo K, Nakahara T, Oeda S, Nagaoki Y, Amano Y, Ando T, Hirayama M, Isono O, Kamiguchi H, Nagabukuro H, Ogawa S, Satomi Y, Saigusa Y, Takahashi H, Hyogo H, Yoneda M, Saito S, Yamanaka T, Aishima S, Eguchi Y, Kage M, Chayama K, Nakajima A. Ogawa Y, et al. Among authors: kobayashi t. Hepatol Res. 2020 Aug;50(8):955-965. doi: 10.1111/hepr.13528. Epub 2020 Jul 15. Hepatol Res. 2020. PMID: 32455496
Comparing the effectiveness of magnesium oxide and naldemedine in preventing opioid-induced constipation: a proof of concept, single institutional, two arm, open-label, phase II, randomized controlled trial: the MAGNET study.
Ozaki A, Kessoku T, Iwaki M, Kobayashi T, Yoshihara T, Kato T, Honda Y, Ogawa Y, Imajo K, Higurashi T, Yoneda M, Taguri M, Yamanaka T, Ishiki H, Kobayashi N, Saito S, Ichikawa Y, Nakajima A. Ozaki A, et al. Among authors: kobayashi n, kobayashi t. Trials. 2020 Jun 1;21(1):453. doi: 10.1186/s13063-020-04385-0. Trials. 2020. PMID: 32487150 Free PMC article.
Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial.
Kessoku T, Imajo K, Kobayashi T, Ozaki A, Iwaki M, Honda Y, Kato T, Ogawa Y, Tomeno W, Kato S, Higurashi T, Yoneda M, Kirikoshi H, Kubota K, Taguri M, Yamanaka T, Usuda H, Wada K, Kobayashi N, Saito S, Nakajima A. Kessoku T, et al. Among authors: kobayashi n, kobayashi t. Lancet Gastroenterol Hepatol. 2020 Nov;5(11):996-1007. doi: 10.1016/S2468-1253(20)30216-8. Epub 2020 Aug 15. Lancet Gastroenterol Hepatol. 2020. PMID: 32805205 Clinical Trial.
Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease.
Kessoku T, Kobayashi T, Ozaki A, Iwaki M, Honda Y, Ogawa Y, Imajo K, Saigusa Y, Yamamoto K, Yamanaka T, Usuda H, Wada K, Yoneda M, Saito S, Nakajima A. Kessoku T, et al. Among authors: kobayashi t. BMJ Open. 2020 Sep 9;10(9):e037961. doi: 10.1136/bmjopen-2020-037961. BMJ Open. 2020. PMID: 32907904 Free PMC article.
Case Reports: Transformation of End-Stage Neuroendocrine Tumors With Uncontrollable Liver Metastasis Into a Novel or Additional Functional Phenotype.
Kessoku T, Kobayashi N, Yoneda M, Kasai Y, Ozaki A, Okubo N, Iwaki M, Kobayashi T, Yoshihara T, Kurita Y, Honda Y, Tokuhisa M, Ishiki H, Hibiya T, Fujii S, Nakajima A, Ichikawa Y. Kessoku T, et al. Among authors: kobayashi n, kobayashi t. Front Oncol. 2020 Sep 25;10:555963. doi: 10.3389/fonc.2020.555963. eCollection 2020. Front Oncol. 2020. PMID: 33102220 Free PMC article.
14,521 results
You have reached the last available page of results. Please see the User Guide for more information.